Last updated on October 2020

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Brief description of study

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Detailed Study Description

This study will be conducted as a 16-week, multi-center, single-arm, open-label study. Pimavanserin will be administered at a dose of 34 mg to approximately 50 subjects with PDP

Clinical Study Identifier: NCT04292223

Find a site near you

Start Over

Meridian Clinical Research

Savannah, GA United States
  Connect »

Bio Behavioral Health

Toms River, NJ United States
  Connect »

@Health Tx

Richmond, TX United States
  Connect »

Central States Research

Tulsa, OK United States
  Connect »

Neurology Associates, P.A.

Maitland, FL United States
  Connect »

Intercoastal Medical Group

Sarasota, FL United States
  Connect »

OrthoNeuro (Optimed)

5040 Forest Drive Suite 300 New Albany, OH United States
  Connect »

Michigan Center of Medical Research

West Bloomfield, MI United States
  Connect »

Neurological Associates of North Texas

9330 Poppy Drive #500b Dallas, Texas United States
  Connect »

Maine Medical Partners Neurology

Scarborough, ME United States
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.